- Home
- AESI vs ZYME Comparison
AESI vs ZYME Comparison
Compare AESI & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AESI
- ZYME
- Stock Information
- Founded
- AESI 2017
- ZYME 2003
- Country
- AESI United States
- ZYME United States
- Employees
- AESI N/A
- ZYME N/A
- Industry
- AESI Metal Fabrications
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- AESI Industrials
- ZYME Health Care
- Exchange
- AESI Nasdaq
- ZYME Nasdaq
- Market Cap
- AESI 1.3B
- ZYME 1.2B
- IPO Year
- AESI 2023
- ZYME 2017
- Fundamental
- Price
- AESI $8.89
- ZYME $18.58
- Analyst Decision
- AESI Buy
- ZYME Strong Buy
- Analyst Count
- AESI 8
- ZYME 7
- Target Price
- AESI $17.06
- ZYME $22.00
- AVG Volume (30 Days)
- AESI 4.2M
- ZYME 1.1M
- Earning Date
- AESI 11-03-2025
- ZYME 11-06-2025
- Dividend Yield
- AESI 11.07%
- ZYME N/A
- EPS Growth
- AESI N/A
- ZYME N/A
- EPS
- AESI N/A
- ZYME N/A
- Revenue
- AESI $1,117,218,000.00
- ZYME $134,481,000.00
- Revenue This Year
- AESI $8.05
- ZYME $99.58
- Revenue Next Year
- AESI $4.38
- ZYME N/A
- P/E Ratio
- AESI N/A
- ZYME N/A
- Revenue Growth
- AESI 20.68
- ZYME 116.21
- 52 Week Low
- AESI $8.18
- ZYME $9.03
- 52 Week High
- AESI $26.86
- ZYME $20.17
- Technical
- Relative Strength Index (RSI)
- AESI 35.33
- ZYME 53.59
- Support Level
- AESI $10.45
- ZYME $16.00
- Resistance Level
- AESI $11.37
- ZYME $20.17
- Average True Range (ATR)
- AESI 0.86
- ZYME 0.89
- MACD
- AESI -0.28
- ZYME -0.05
- Stochastic Oscillator
- AESI 15.46
- ZYME 62.32
About AESI Atlas Energy Solutions Inc.
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.